Physician profile
William C Denney
NPI 1366888505
$10,767.43
in general payments reported to CMS, 2019-2025
38 companies · $2,387 in 2025
The $2,387 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $407 · 2021: $1,459 · 2022: $1,299 · 2023: $2,173 · 2024: $1,960 · 2025: $2,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,102 · Travel and Lodging: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,102.48 |
| Travel and Lodging | $417.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,202.51 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,185.16 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Actelion Pharmaceuticals US, INC. | $956.14 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $635.87 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Intuitive Surgical, INC. | $539.17 | 2021-2023 | Da Vinci Surgical System |
| Mallinckrodt Hospital Products INC. | $424.97 | 2020-2025 | Acthar |
| Genzyme Corporation | $415.92 | 2021-2025 | |
| United Therapeutics Corporation | $368.15 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Mylan Specialty L.P. | $285.60 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $246.77 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $240.46 | 2023-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $236.16 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $233.92 | 2020-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $223.93 | 2021-2025 | Zerbaxa, Winrevair, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $179.93 | 2021-2025 | Glassia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $171.85 | 2019-2022 | |
| Verona Pharma, INC. | $160.28 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $136.95 | 2019-2020 | |
| Pfizer INC. | $127.97 | 2020-2025 | |
| Insmed, INC. | $109.53 | 2021-2025 | Arikayce, Brinsupri |
| E.R. Squibb & Sons, L.L.C. | $97.58 | 2020-2023 | Eliquis |
| Mallinckrodt Enterprises LLC | $90.08 | 2019 | |
| Viatris Specialty LLC | $77.68 | 2025 | Yupelri |
| Electromed, INC. | $61.53 | 2024-2025 | Smartvest |
| Ani Pharmaceuticals, INC. | $47.24 | 2024-2025 | Purified Cortrophin Gel |
| Advanced Respiratory, INC | $40.32 | 2021 | |
| Amgen INC. | $37.69 | 2024-2025 | Tezspire |
| Liquidia Technologies, INC. | $35.64 | 2025 | Yutrepia |
| Tetraphase Pharmaceuticals, INC. | $29.95 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.23 | 2019-2020 | |
| Vapotherm INC | $24.26 | 2020 | |
| Axsome Therapeutics, INC. | $22.68 | 2023 | Sunosi |
| Baxter Healthcare | $18.15 | 2022 | |
| Portola Pharmaceuticals, LLC | $17.52 | 2019 | |
| Pulmonx Corporation | $17.23 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Gilead Sciences, INC. | $13.49 | 2021 | |
| Nabriva Therapeutics, Plc | $13.32 | 2021 | |
| La Jolla Pharmaceutical Company | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Denney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.